OQROGet OQRO Pro
Politician trade (House)

Pfizer (PFE)Rep. Carol Devine Miller (WV01) disclosed a sale $15K–$50K

Rep. Carol Devine Miller (WV01) disclosed a sale of Pfizer in the $15K–$50K range.

$15,001–$50,000
Reported range · official band, not an exact amount
521 days
Disclosure lag
Traded
Mar 10, 2025
Disclosed
Aug 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 15, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  2. Jan 24, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  3. Jan 31, 2025FDAFDA drug approval: Paxlovid (Copackaged)
  4. Feb 12, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  5. Feb 13, 2025InsiderDirector purchased ~$499K of PFE shares in the open market
  6. Feb 13, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  7. Feb 21, 2025FDAFDA drug approval: Xeljanz
  8. Feb 21, 2025FDAFDA drug approval: Xeljanz XR
  9. Feb 24, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
  10. Feb 25, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
  11. Feb 26, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  12. Mar 3, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  13. Mar 4, 2025InsiderOfficer sold ~$65K of PFE shares in the open market
  14. Mar 10, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000

What came next

  1. Mar 12, 2025FDAFDA drug approval: Mektovi
  2. Mar 12, 2025FDAFDA drug approval: Braftovi
  3. Mar 31, 2025Congress · 1 personMembers of Congress: 2 sales
  4. Apr 8, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  5. Apr 11, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  6. Apr 21, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  7. Apr 23, 2025FDAFDA drug approval: Ibrance
  8. Apr 23, 2025FDAFDA drug approval: Ibrance
  9. Apr 29, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  10. May 15, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
  11. May 28, 2025FDARecall: DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, For Intravenous Use Only, Made in Italy,…
  12. May 30, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  13. Jun 3, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  14. Jun 12, 2025FDAFDA drug approval: Talzenna
  15. Jun 12, 2025FDAFDA drug approval: Talzenna
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Pfizer

For Pfizer, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Rep. Carol Devine Miller (WV01)

The full history of Rep. Carol Devine Miller (WV01) is on the profile page.

How this filing works

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data